Shanghai Serum Bio-Technology Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shanghai Serum Bio-Technology Co., Ltd.

Why is Shanghai Serum Bio-Technology Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 16.43%

The company has been able to generate a Return on Capital Employed (avg) of 16.43% signifying low profitability per unit of total capital (equity and debt)

Poor long term growth as Net Sales has grown by an annual rate of 1.64% and Operating profit at 5.83% over the last 5 years

Flat results in Sep 25

DEBT-EQUITY RATIO (HY) Highest at -69.53 %
DEBTORS TURNOVER RATIO(HY) Lowest at 2.83 times

With ROE of 3.97%, it has a fair valuation with a 0.92 Price to Book Value

Over the past year, while the stock has generated a return of 34.79%, its profits have risen by 0.8%

Market Beating Performance

The stock has generated a return of 34.79% in the last 1 year, much higher than market (China Shanghai Composite) returns of 22.49%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Shanghai Serum Bio-Technology Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shanghai Serum Bio-Technology Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Shanghai Serum Bio-Technology Co., Ltd.

43.8%

2.59

38.15%

China Shanghai Composite

16.01%

1.58

14.20%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.64%

EBIT Growth (5y)

5.83%

EBIT to Interest (avg)

40.36

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.73

Sales to Capital Employed (avg)

0.18

Tax Ratio

10.03%

Dividend Payout Ratio

78.18%

Pledged Shares

Institutional Holding

ROCE (avg)

16.43%

ROE (avg)

4.24%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.92

EV to EBIT

5.67

EV to EBITDA

3.98

EV to Capital Employed

0.74

EV to Sales

1.30

PEG Ratio

Dividend Yield

ROCE (Latest)

13.06%

ROE (Latest)

3.97%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -1.32% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 1.32 times

NET PROFIT(Q)

Highest at CNY 31.72 MM

EPS(Q)

Highest at CNY 0.29

-3What is not working for the Company

DEBT-EQUITY RATIO (HY)

Highest at -69.53 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.83 times

Here's what is working for Shanghai Serum Bio-Technology Co., Ltd.

Net Profit

Highest at CNY 31.72 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.29

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Inventory Turnover Ratio

Highest at 1.32 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by -1.32% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shanghai Serum Bio-Technology Co., Ltd.

Debt-Equity Ratio

Highest at -69.53 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 2.83 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio